Moxetumomab pasudotox

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1020748-57-5

CAT 8015
HA 22
Anti-Human CD22 Recombinant Antibody

Moxetumomab pasudotox (CAT 8015) 是一种抗CD22免疫毒素，含有抗 CD22 F_v和Pseudomonas exotoxin。CD22 是在多种恶性 B 细胞上表达的细胞表面受体。Moxetumomab pasudotox 可用于毛细胞白血病 (HCL) 的研究。

生物活性

Moxetumomab pasudotox (CAT 8015) isanti-CD22immunotoxin containing an anti-CD22 F_vandPseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL)^[1]^[2]^[3].

体外研究
(In Vitro)

Moxetumomab pasudotox (0-10 mg/mL, 66 h) reduces cell viability of BCP-ALL cells (determined by Annexin-V negative)^[3].
The binding and internalization of MP/CD22 complexes is correlated with pre-B ALL cell line responses to MP^[5].

体内研究
(In Vivo)

Moxetumomab pasudotox (300 mg/kg, i.v., every other day) prolongs median survival in 697 cell model (P< 0.0001)^[3].
Moxetumomab pasudotox (0.4 mg/kg, i.v. three doses, every other day) clears the bone marrow (BM) from acute lymphoblastic leukemia (ALL), but disease relapses from discrete BM-sites in NSG mouse model^[4].

Animal Model:	NSG (NOD.Cg-Prkdc^scidIl2rg^tm1Wjl/SzJ) mouse model^[4]
Dosage:	0.4 mg/kg
Administration:	Intravenous injection (i.v.), three doses, every other day.
Result:	Survived much longer but died from ALL after 40 d. Reduced BM-infiltration to 4% on day 8.

分子量

63.5 (kDa)

CAS 号

1020748-57-5

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.